Fortress Biotech, Inc. (FBIO): Price and Financial Metrics


Fortress Biotech, Inc. (FBIO): $3.25

0.02 (+0.62%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FBIO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 491

in industry

FBIO POWR Grades


  • FBIO scores best on the Sentiment dimension, with a Sentiment rank ahead of 98.62% of US stocks.
  • The strongest trend for FBIO is in Momentum, which has been heading down over the past 52 weeks.
  • FBIO ranks lowest in Momentum; there it ranks in the 9th percentile.

FBIO Stock Summary

  • Of note is the ratio of Fortress Biotech Inc's sales and general administrative expense to its total operating expenses; only 22.78% of US stocks have a lower such ratio.
  • With a price/sales ratio of 6.2, Fortress Biotech Inc has a higher such ratio than 73.03% of stocks in our set.
  • In terms of twelve month growth in earnings before interest and taxes, Fortress Biotech Inc is reporting a growth rate of -53.13%; that's higher than 27.59% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Fortress Biotech Inc, a group of peers worth examining would be ARDX, INSM, CDXS, CLVS, and CRDF.
  • Visit FBIO's SEC page to see the company's official filings. To visit the company's web site, go to www.fortressbiotech.com.

FBIO Valuation Summary

  • In comparison to the median Healthcare stock, FBIO's price/sales ratio is 44.49% lower, now standing at 6.3.
  • FBIO's price/earnings ratio has moved down 2.3 over the prior 119 months.
  • FBIO's price/sales ratio has moved NA NA over the prior 119 months.

Below are key valuation metrics over time for FBIO.

Stock Date P/S P/B P/E EV/EBIT
FBIO 2021-08-31 6.3 3.1 -10.0 -7.0
FBIO 2021-08-30 6.2 3.0 -9.9 -6.8
FBIO 2021-08-27 6.2 3.0 -9.9 -6.8
FBIO 2021-08-26 5.9 2.9 -9.4 -5.9
FBIO 2021-08-25 6.2 3.0 -9.8 -6.6
FBIO 2021-08-24 6.2 3.0 -9.9 -6.7

FBIO Growth Metrics

  • Its 4 year price growth rate is now at -12%.
  • Its 3 year net income to common stockholders growth rate is now at -27.09%.
  • Its 4 year net income to common stockholders growth rate is now at -10.59%.
FBIO's revenue has moved up $51,791,000 over the prior 67 months.

The table below shows FBIO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 52.654 -100.526 -33.199
2021-03-31 44.268 -83.478 -42.978
2020-12-31 45.599 -83.682 -46.526
2020-12-31 45.599 -83.682 -46.526
2020-09-30 42.98 -88.248 -56.723
2020-06-30 43.277 -80.62 -53.938

FBIO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FBIO has a Quality Grade of D, ranking ahead of 15.25% of graded US stocks.
  • FBIO's asset turnover comes in at 0.147 -- ranking 224th of 680 Pharmaceutical Products stocks.
  • MTEX, SRNE, and TVTX are the stocks whose asset turnover ratios are most correlated with FBIO.

The table below shows FBIO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.147 0.638 -0.159
2021-03-31 0.138 0.668 -0.248
2020-12-31 0.163 0.680 -0.265
2020-12-31 0.163 0.680 -0.265
2020-09-30 0.169 0.677 -0.339
2020-06-30 0.183 0.695 -0.332

FBIO Price Target

For more insight on analysts targets of FBIO, see our FBIO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.17 Average Broker Recommendation 1.5 (Moderate Buy)

FBIO Stock Price Chart Interactive Chart >

Price chart for FBIO

FBIO Price/Volume Stats

Current price $3.25 52-week high $6.10
Prev. close $3.23 52-week low $2.12
Day low $3.18 Volume 453,100
Day high $3.28 Avg. volume 1,017,695
50-day MA $3.21 Dividend yield N/A
200-day MA $3.63 Market Cap 328.45M

Fortress Biotech, Inc. (FBIO) Company Bio


Fortress Biotech, Inc., a biopharmaceutical company, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer. The company was founded in 2006 and is based in New York, New York.


FBIO Latest News Stream


Event/Time News Detail
Loading, please wait...

FBIO Latest Social Stream


Loading social stream, please wait...

View Full FBIO Social Stream

Latest FBIO News From Around the Web

Below are the latest news stories about Fortress Biotech Inc that investors may wish to consider to help them evaluate FBIO as an investment opportunity.

Avenue Therapeutics Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Administration Office of New Drugs

Office of New Drugs concludes that additional input is needed, and U.S. Food and Drug Administration will convene an Advisory Committee meetingNEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that it has received a written interim response from the Office of New Drugs (“OND”) of the U.S. Food and Drug Administration (“FDA”). The letter indicated

Yahoo | October 25, 2021

Fortress Biotech to Participate in Dawson James Securities’ 6th Annual Small Cap Growth Conference

NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate update at Dawson James Securities’ 6th Annual Small Cap Growth Conference on Thursday, October 2

Yahoo | October 18, 2021

18 Stocks Moving in Thursday's Pre-Market Session

Gainers TSR, Inc. (NASDAQ: TSRI) rose 40.2% to $12.89 in pre-market trading after the company reported record revenue for its first quarter. Cemtrex, Inc. (NASDAQ: CETX) rose 34.3% to $1.39 in pre-market trading after jumping 15% on Wednesday. KORE Wireless Group, Inc. (NYSE: KORE) rose 25.8% to $7.95 in pre-market trading. Esports Entertainment Group, Inc. (NASDAQ: GMBL) rose 16.2% to $7.69 in pre-market trading after the company posted Q4 results and issued FY22 sales guidance above estimates.

Yahoo | October 14, 2021

Fortress' (FBIO) Partner Meets Study Goal for Menkes Disease

Cyprium Therapeutics, a partner company of Fortress Biotech (FBIO), reports positive data from two pivotal studies evaluating CUTX-101 in patients with Menkes disease.

Yahoo | October 11, 2021

Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition

Cyprium Therapeutics, a partner company of Fortress Biotech, is developing CUTX-101 for the treatment of Menkes disease Overall survival significantly improved in patients treated with CUTX-101 Rolling submission of New Drug Application to the FDA for CUTX-101 planned to begin in fourth quarter of 2021; potential to be first FDA-approved treatment for Menkes disease NEW The post Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition appeared first on ForexTV .

ForexTV | October 8, 2021

Read More 'FBIO' Stories Here

FBIO Price Returns

1-mo -4.41%
3-mo 4.50%
6-mo -24.77%
1-year 40.39%
3-year 218.63%
5-year 32.65%
YTD 2.52%
2020 23.35%
2019 198.84%
2018 -78.45%
2017 47.78%
2016 -3.23%

Continue Researching FBIO

Here are a few links from around the web to help you further your research on Fortress Biotech Inc's stock as an investment opportunity:

Fortress Biotech Inc (FBIO) Stock Price | Nasdaq
Fortress Biotech Inc (FBIO) Stock Quote, History and News - Yahoo Finance
Fortress Biotech Inc (FBIO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8047 seconds.